Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Vaxcyte, Inc.PCVX · Entity 1164 | EVP, Chief Scientific Ofc, COO | October 05, 2026 | October 07, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Vaxcyte, Inc.
Report date October 05, 2026 · Filed October 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 145,435 |
Ending reported balance
After 2026-10-05 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-10-05 · Exercise / conversion · Acquired 18,000 · Balance 163,435 Row 2 · 2026-10-05 · Sale · Disposed 18,000 · Balance 145,435 F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on December 9, 2025. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.35 · Expires 2030-04-17 | Direct | 46,398 |
Reported balance
After 2026-10-05 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-10-05 · Exercise / conversion · Disposed 18,000 · Balance 46,398 F2: Stock Option is fully vested and exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on December 9, 2025.
F2: Stock Option is fully vested and exercisable.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Icosavax, Inc.
Report date February 19, 2024 · Filed February 21, 2024
Section 16 reporting ended · disclosed 2024-02-21. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-02-19 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2024-02-19 · Other · Disposed 3,695 · Balance 0 F1: In connection with the terms of an Agreement and Plan of Merger, dated as of December 11, 2023 (the "Merger Agreement"), by and among the Issuer, AstraZeneca Finance and Holdings Inc. ("Parent"), and Isochrone Merger Sub Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's Common Stock at a purchase price per share of (i) $15.00 plus (ii) one non-tradable contingent value right ("CVR") per share representing the right to receive a contingent payment of up to $5.00 in cash upon achievement of specified milestones (collectively, the "Offer Price"). After completion of the tender offer, Purchaser merged with and into the Issuer (the "Merger"), effective as of February 19, 2024 (the "Effective Time"), with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-02-19 transaction · row 2
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 2 · 2024-02-19 · Disposition to issuer · Disposed 7,392 · Balance 0 F2: Represents restricted stock units ("RSUs"). Pursuant to the Merger Agreement, immediately prior to the Effective Time, each RSU that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the contingent right to receive the Offer Price, subject to the terms of the Merger Agreement. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.25 | Direct | 0 |
Reported balance
After 2024-02-19 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-02-19 · Disposition to issuer · Disposed 44,556 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, this stock option was cancelled and converted into the right to receive, subject to the terms of the Merger Agreement, (a) an amount in cash equal to the product obtained by multiplying (1) the aggregate number of shares underlying such option immediately prior to the Effective Time by (2) an amount equal to (A) $15.00 less (B) the exercise price of such option, plus (b) one CVR for each share underlying such option immediately prior to the Effective Time. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.89 | Direct | 0 |
Reported balance
After 2024-02-19 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-02-19 · Disposition to issuer · Disposed 17,000 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, this stock option was cancelled and converted into the right to receive, subject to the terms of the Merger Agreement, (a) an amount in cash equal to the product obtained by multiplying (1) the aggregate number of shares underlying such option immediately prior to the Effective Time by (2) an amount equal to (A) $15.00 less (B) the exercise price of such option, plus (b) one CVR for each share underlying such option immediately prior to the Effective Time. |
Filing footnotes · ownership attribution and instrument terms
F1: In connection with the terms of an Agreement and Plan of Merger, dated as of December 11, 2023 (the "Merger Agreement"), by and among the Issuer, AstraZeneca Finance and Holdings Inc. ("Parent"), and Isochrone Merger Sub Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's Common Stock at a purchase price per share of (i) $15.00 plus (ii) one non-tradable contingent value right ("CVR") per share representing the right to receive a contingent payment of up to $5.00 in cash upon achievement of specified milestones (collectively, the "Offer Price"). After completion of the tender offer, Purchaser merged with and into the Issuer (the "Merger"), effective as of February 19, 2024 (the "Effective Time"), with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent.
F2: Represents restricted stock units ("RSUs"). Pursuant to the Merger Agreement, immediately prior to the Effective Time, each RSU that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the contingent right to receive the Offer Price, subject to the terms of the Merger Agreement.
F3: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, this stock option was cancelled and converted into the right to receive, subject to the terms of the Merger Agreement, (a) an amount in cash equal to the product obtained by multiplying (1) the aggregate number of shares underlying such option immediately prior to the Effective Time by (2) an amount equal to (A) $15.00 less (B) the exercise price of such option, plus (b) one CVR for each share underlying such option immediately prior to the Effective Time.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 03, 2024 Filed Sep 5, 2024 21:19 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 389 | $114.25 | $44,444.73 |
DisclosureSEC source: 0001649094-24-000066 · wk-form4_1725571164.xml · nonDerivative · entry 7 Wassil Jim · CIK 0001813798 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 209,052 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on March 1, 2024. F7 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $113.84 to $114.80. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 21:19 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 367 | $112.95 | $41,451.59 |
DisclosureSEC source: 0001649094-24-000066 · wk-form4_1725571164.xml · nonDerivative · entry 6 Wassil Jim · CIK 0001813798 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 209,441 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on March 1, 2024. F6 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $112.57 to $113.18. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 21:19 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 2,263 | $111.85 | $253,107.05 |
DisclosureSEC source: 0001649094-24-000066 · wk-form4_1725571164.xml · nonDerivative · entry 5 Wassil Jim · CIK 0001813798 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 209,808 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on March 1, 2024. F5 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $111.48 to $112.41. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 21:19 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 3,102 | $111.02 | $344,388.38 |
DisclosureSEC source: 0001649094-24-000066 · wk-form4_1725571164.xml · nonDerivative · entry 4 Wassil Jim · CIK 0001813798 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 212,071 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on March 1, 2024. F4 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $110.43 to $111.42. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 21:19 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 2,072 | $110.08 | $228,084.52 |
DisclosureSEC source: 0001649094-24-000066 · wk-form4_1725571164.xml · nonDerivative · entry 3 Wassil Jim · CIK 0001813798 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 215,173 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on March 1, 2024. F3 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $109.415 to $110.40. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 21:19 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 258 | $108.01 | $27,867.25 |
DisclosureSEC source: 0001649094-24-000066 · wk-form4_1725571164.xml · nonDerivative · entry 2 Wassil Jim · CIK 0001813798 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 217,245 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on March 1, 2024. F2 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $107.67 to $108.425. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 21:19 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 10,000 | $2.42 | $24,200.00 |
DisclosureSEC source: 0001649094-24-000066 · wk-form4_1725571164.xml · nonDerivative · entry 1 Wassil Jim · CIK 0001813798 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 217,503 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 01, 2024 Filed Aug 5, 2024 20:10 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 23 | $79.47 | $1,827.81 |
DisclosureSEC source: 0001649094-24-000044 · wk-form4_1722888630.xml · nonDerivative · entry 2 Wassil Jim · CIK 0001813798 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 207,503 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on May 23, 2023. Read SEC document |
| August 01, 2024 Filed Aug 5, 2024 20:10 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 2,977 | $78.84 | $234,699.24 |
DisclosureSEC source: 0001649094-24-000044 · wk-form4_1722888630.xml · nonDerivative · entry 1 Wassil Jim · CIK 0001813798 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 207,526 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on May 23, 2023. F2 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $78.28 to $79.23. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| July 01, 2024 Filed Jul 2, 2024 20:16 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 111 | $77.22 | $8,570.87 |
DisclosureSEC source: 0001649094-24-000027 · wk-form4_1719951391.xml · nonDerivative · entry 3 Wassil Jim · CIK 0001813798 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 210,503 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on May 23, 2023. Read SEC document |
| July 01, 2024 Filed Jul 2, 2024 20:16 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 1,663 | $76.71 | $127,566.40 |
DisclosureSEC source: 0001649094-24-000027 · wk-form4_1719951391.xml · nonDerivative · entry 2 Wassil Jim · CIK 0001813798 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 210,614 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on May 23, 2023. F3 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $76.21 to $77.14. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| July 01, 2024 Filed Jul 2, 2024 20:16 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 1,226 | $75.75 | $92,875.38 |
DisclosureSEC source: 0001649094-24-000027 · wk-form4_1719951391.xml · nonDerivative · entry 1 Wassil Jim · CIK 0001813798 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 212,277 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on May 23, 2023. F2 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $75.21 to $76.20. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 03, 2024 Filed Jun 5, 2024 20:57 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 460 | $73.48 | $33,798.50 |
DisclosureSEC source: 0001415889-24-015587 · form4-06052024_080638.xml · nonDerivative · entry 3 Wassil Jim · CIK 0001813798 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 213,503 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on May 23, 2023. F5 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $73.41 to $73.54. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 03, 2024 Filed Jun 5, 2024 20:57 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 906 | $72.32 | $65,521.01 |
DisclosureSEC source: 0001415889-24-015587 · form4-06052024_080638.xml · nonDerivative · entry 2 Wassil Jim · CIK 0001813798 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 213,964 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on May 23, 2023. F4 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $72.01 to $72.67. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 03, 2024 Filed Jun 5, 2024 20:57 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 1,634 | $71.38 | $116,641.46 |
DisclosureSEC source: 0001415889-24-015587 · form4-06052024_080638.xml · nonDerivative · entry 1 Wassil Jim · CIK 0001813798 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 214,869 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on May 23, 2023. F2 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $70.98 to $71.94. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes 1,041 shares acquired under the Issuer's Employee Stock Purchase Plan on May 17, 2024. Read SEC document |
| May 01, 2024 Filed May 3, 2024 20:19 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 185 | $63.65 | $11,774.51 |
DisclosureSEC source: 0001415889-24-012166 · form4-05032024_080545.xml · nonDerivative · entry 3 Wassil Jim · CIK 0001813798 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 215,462 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on May 23, 2023. F5 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $63.37 to $63.905. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 01, 2024 Filed May 3, 2024 20:19 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 1,062 | $61.99 | $65,836.57 |
DisclosureSEC source: 0001415889-24-012166 · form4-05032024_080545.xml · nonDerivative · entry 2 Wassil Jim · CIK 0001813798 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 215,647 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on May 23, 2023. F4 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $61.775 to $62.36. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 01, 2024 Filed May 3, 2024 20:19 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 1,753 | $61.23 | $107,330.93 |
DisclosureSEC source: 0001415889-24-012166 · form4-05032024_080545.xml · nonDerivative · entry 1 Wassil Jim · CIK 0001813798 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 216,709 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on May 23, 2023. F2 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $60.76 to $61.495. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. F3 · balance_after: The Reporting Person has entered into a divorce settlement agreement with his ex-spouse (the "Settlement Agreement") pursuant to a "domestic relations order" as defined in Section 16(a)(12) of the Securities Exchange Act of 1934, as amended. Since the date of the Reporting Person's ownership report filed on April 19, 2024, the Reporting Person transferred 3,378 shares of Vaxcyte, Inc. Common Stock to his ex-spouse pursuant to the Settlement Agreement. Accordingly, the Reporting Person will not report beneficial ownership of or dispositions of the disposed shares in future Section 16(a) filings. Read SEC document |
| April 17, 2024 Filed Apr 19, 2024 20:31 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 3,551 | $0.00 Strike: $5.35 | $0.00 |
DisclosureSEC source: 0001415889-24-011233 · form4-04192024_080438.xml · derivative · entry 2 Wassil Jim · CIK 0001813798 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,611 Underlying: Common Stock · 3,551 shares Expires 2030-04-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Stock Option is fully vested and exercisable. Read SEC document |
| April 17, 2024 Filed Apr 19, 2024 20:31 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 3,551 | $5.35 | $18,997.85 |
DisclosureSEC source: 0001415889-24-011233 · form4-04192024_080438.xml · nonDerivative · entry 1 Wassil Jim · CIK 0001813798 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 221,840 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 01, 2024 Filed Apr 3, 2024 20:22 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 677 | $67.23 | $45,514.03 |
DisclosureSEC source: 0001415889-24-010000 · form4-04032024_080400.xml · nonDerivative · entry 2 Wassil Jim · CIK 0001813798 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 218,289 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on May 23, 2023. F3 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $67.13 to $68.10. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 01, 2024 Filed Apr 3, 2024 20:22 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 2,323 | $66.53 | $154,551.51 |
DisclosureSEC source: 0001415889-24-010000 · form4-04032024_080400.xml · nonDerivative · entry 1 Wassil Jim · CIK 0001813798 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 218,966 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on May 23, 2023. F2 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $66.09 to $67.07. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 15, 2024 Filed Mar 19, 2024 20:26 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Tax withholdingCommon Stock | 1,484 | $69.70 | $103,434.80 |
DisclosureSEC source: 0001415889-24-008520 · form4-03192024_080334.xml · nonDerivative · entry 2 Wassil Jim · CIK 0001813798 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 221,289 F2 · shares: Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of RSUs. Read SEC document |
| March 15, 2024 Filed Mar 19, 2024 20:26 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantCommon Stock | 4,099 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-008520 · form4-03192024_080334.xml · nonDerivative · entry 1 Wassil Jim · CIK 0001813798 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 222,773 F1 · shares: Represents the number of shares of Common Stock underlying restricted stock units ("RSUs") issued in lieu of a cash bonus by election of the Reporting Person, such election available to all of Issuer's senior management. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs are fully vested upon the date of grant. Read SEC document |
| March 02, 2024 Filed Mar 5, 2024 02:23 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Tax withholdingCommon Stock | 2,178 | $71.55 | $155,835.90 |
DisclosureSEC source: 0001415889-24-006476 · form4-03052024_020303.xml · nonDerivative · entry 5 Wassil Jim · CIK 0001813798 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 218,674 F6 · shares: Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of restricted stock units. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 02:23 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 763 | $74.70 | $56,992.29 |
DisclosureSEC source: 0001415889-24-006476 · form4-03052024_020303.xml · nonDerivative · entry 4 Wassil Jim · CIK 0001813798 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 220,852 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on May 23, 2023. F5 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $74.46 to $75.02. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 02:23 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 1,220 | $73.62 | $89,821.28 |
DisclosureSEC source: 0001415889-24-006476 · form4-03052024_020303.xml · nonDerivative · entry 3 Wassil Jim · CIK 0001813798 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 221,615 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on May 23, 2023. F4 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $73.42 to $74.36. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 02:23 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 1,017 | $73.08 | $74,320.33 |
DisclosureSEC source: 0001415889-24-006476 · form4-03052024_020303.xml · nonDerivative · entry 2 Wassil Jim · CIK 0001813798 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 222,835 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on May 23, 2023. F3 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $72.39 to $73.355. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 29, 2024 Filed Mar 5, 2024 02:23 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantStock Option (right to buy) · Derivative | 90,000 | $0.00 Strike: $73.82 | $0.00 |
DisclosureSEC source: 0001415889-24-006476 · form4-03052024_020303.xml · derivative · entry 6 Wassil Jim · CIK 0001813798 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2034-02-28 F7 · derivative.exercise_date: 1/48 of shares subject to the option vest on March 31, 2024, and 1/48 of the shares vest monthly thereafter, subject to Reporting Person's continuous service with the Issuer through each such date. Read SEC document |
| February 29, 2024 Filed Mar 5, 2024 02:23 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-006476 · form4-03052024_020303.xml · nonDerivative · entry 1 Wassil Jim · CIK 0001813798 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 223,852 F1 · shares: Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs vest as to 25% of the shares subject to the award on August 31, 2024 and 12.5% of the shares every six months thereafter, subject to Reporting Person's continuous service with the Issuer through each such date. Read SEC document |
| February 19, 2024 Filed Feb 21, 2024 00:44 UTC | Icosavax, Inc. ICVX · Entity 94107 | Disposition to issuerStock Option (Right to Buy) · Derivative | 17,000 | Not disclosed Strike: $9.89 | Not disclosed |
DisclosureSEC source: 0000950170-24-017412 · ownership.xml · derivative · entry 4 Wassil Jim · CIK 0001813798 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,000 shares Expires not disclosed F3 · price: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, this stock option was cancelled and converted into the right to receive, subject to the terms of the Merger Agreement, (a) an amount in cash equal to the product obtained by multiplying (1) the aggregate number of shares underlying such option immediately prior to the Effective Time by (2) an amount equal to (A) $15.00 less (B) the exercise price of such option, plus (b) one CVR for each share underlying such option immediately prior to the Effective Time. F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, this stock option was cancelled and converted into the right to receive, subject to the terms of the Merger Agreement, (a) an amount in cash equal to the product obtained by multiplying (1) the aggregate number of shares underlying such option immediately prior to the Effective Time by (2) an amount equal to (A) $15.00 less (B) the exercise price of such option, plus (b) one CVR for each share underlying such option immediately prior to the Effective Time. F3 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, this stock option was cancelled and converted into the right to receive, subject to the terms of the Merger Agreement, (a) an amount in cash equal to the product obtained by multiplying (1) the aggregate number of shares underlying such option immediately prior to the Effective Time by (2) an amount equal to (A) $15.00 less (B) the exercise price of such option, plus (b) one CVR for each share underlying such option immediately prior to the Effective Time. Read SEC document |
| February 19, 2024 Filed Feb 21, 2024 00:44 UTC | Icosavax, Inc. ICVX · Entity 94107 | Disposition to issuerStock Option (Right to Buy) · Derivative | 44,556 | Not disclosed Strike: $6.25 | Not disclosed |
DisclosureSEC source: 0000950170-24-017412 · ownership.xml · derivative · entry 3 Wassil Jim · CIK 0001813798 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 44,556 shares Expires not disclosed F3 · price: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, this stock option was cancelled and converted into the right to receive, subject to the terms of the Merger Agreement, (a) an amount in cash equal to the product obtained by multiplying (1) the aggregate number of shares underlying such option immediately prior to the Effective Time by (2) an amount equal to (A) $15.00 less (B) the exercise price of such option, plus (b) one CVR for each share underlying such option immediately prior to the Effective Time. F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, this stock option was cancelled and converted into the right to receive, subject to the terms of the Merger Agreement, (a) an amount in cash equal to the product obtained by multiplying (1) the aggregate number of shares underlying such option immediately prior to the Effective Time by (2) an amount equal to (A) $15.00 less (B) the exercise price of such option, plus (b) one CVR for each share underlying such option immediately prior to the Effective Time. F3 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, this stock option was cancelled and converted into the right to receive, subject to the terms of the Merger Agreement, (a) an amount in cash equal to the product obtained by multiplying (1) the aggregate number of shares underlying such option immediately prior to the Effective Time by (2) an amount equal to (A) $15.00 less (B) the exercise price of such option, plus (b) one CVR for each share underlying such option immediately prior to the Effective Time. Read SEC document |
| February 19, 2024 Filed Feb 21, 2024 00:44 UTC | Icosavax, Inc. ICVX · Entity 94107 | Disposition to issuerCommon Stock | 7,392 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-017412 · ownership.xml · nonDerivative · entry 2 Wassil Jim · CIK 0001813798 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F2 · shares: Represents restricted stock units ("RSUs"). Pursuant to the Merger Agreement, immediately prior to the Effective Time, each RSU that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the contingent right to receive the Offer Price, subject to the terms of the Merger Agreement. F2 · price: Represents restricted stock units ("RSUs"). Pursuant to the Merger Agreement, immediately prior to the Effective Time, each RSU that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the contingent right to receive the Offer Price, subject to the terms of the Merger Agreement. Read SEC document |
| February 19, 2024 Filed Feb 21, 2024 00:44 UTC | Icosavax, Inc. ICVX · Entity 94107 | OtherCommon Stock | 3,695 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-017412 · ownership.xml · nonDerivative · entry 1 Wassil Jim · CIK 0001813798 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: In connection with the terms of an Agreement and Plan of Merger, dated as of December 11, 2023 (the "Merger Agreement"), by and among the Issuer, AstraZeneca Finance and Holdings Inc. ("Parent"), and Isochrone Merger Sub Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's Common Stock at a purchase price per share of (i) $15.00 plus (ii) one non-tradable contingent value right ("CVR") per share representing the right to receive a contingent payment of up to $5.00 in cash upon achievement of specified milestones (collectively, the "Offer Price"). After completion of the tender offer, Purchaser merged with and into the Issuer (the "Merger"), effective as of February 19, 2024 (the "Effective Time"), with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent. Read SEC document |
| February 15, 2024 Filed Feb 20, 2024 21:22 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 27,917 | $0.00 Strike: $2.42 | $0.00 |
DisclosureSEC source: 0001415889-24-004352 · form4-02202024_090202.xml · derivative · entry 2 Wassil Jim · CIK 0001813798 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,638 Underlying: Common Stock · 27,917 shares Expires 2029-12-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 1/4 of the shares subject to the option vested on December 1, 2020, and 1/48 of the shares vest monthly thereafter. Read SEC document |
| February 15, 2024 Filed Feb 20, 2024 21:22 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 27,917 | $2.42 | $67,559.14 |
DisclosureSEC source: 0001415889-24-004352 · form4-02202024_090202.xml · nonDerivative · entry 1 Wassil Jim · CIK 0001813798 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 203,852 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 22:37 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 3,000 | $0.00 Strike: $2.42 | $0.00 |
DisclosureSEC source: 0001415889-24-002612 · form4-02052024_100231.xml · derivative · entry 6 Wassil Jim · CIK 0001813798 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 90,555 Underlying: Common Stock · 3,000 shares Expires 2029-12-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: 1/4 of the shares subject to the option vested on December 1, 2020, and 1/48 of the shares vest monthly thereafter. Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 22:37 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 950 | $75.28 | $71,515.05 |
DisclosureSEC source: 0001415889-24-002612 · form4-02052024_100231.xml · nonDerivative · entry 5 Wassil Jim · CIK 0001813798 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 175,935 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on May 23, 2023. F5 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $74.80 to $75.69. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 22:37 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 467 | $74.14 | $34,621.51 |
DisclosureSEC source: 0001415889-24-002612 · form4-02052024_100231.xml · nonDerivative · entry 4 Wassil Jim · CIK 0001813798 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 176,885 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on May 23, 2023. F4 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $73.77 to $74.765. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 22:37 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 1,056 | $73.35 | $77,452.32 |
DisclosureSEC source: 0001415889-24-002612 · form4-02052024_100231.xml · nonDerivative · entry 3 Wassil Jim · CIK 0001813798 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 177,352 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on May 23, 2023. F3 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $72.71 to $73.69. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 22:37 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 527 | $72.18 | $38,037.28 |
DisclosureSEC source: 0001415889-24-002612 · form4-02052024_100231.xml · nonDerivative · entry 2 Wassil Jim · CIK 0001813798 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 178,408 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on May 23, 2023. F2 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $71.69 to $72.51. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 22:37 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 3,000 | $2.42 | $7,260.00 |
DisclosureSEC source: 0001415889-24-002612 · form4-02052024_100231.xml · nonDerivative · entry 1 Wassil Jim · CIK 0001813798 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 178,935 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 21:25 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 3,000 | $0.00 Strike: $2.42 | $0.00 |
DisclosureSEC source: 0001209191-24-000780 · doc4.xml · derivative · entry 6 Wassil Jim · CIK 0001813798 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 93,555 Underlying: Common Stock · 3,000 shares Expires 2029-12-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 1/4 of the shares subject to the option vested on December 1, 2020, and 1/48 of the shares vest monthly thereafter. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 21:25 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 110 | $65.15 | $7,166.50 |
DisclosureSEC source: 0001209191-24-000780 · doc4.xml · nonDerivative · entry 5 Wassil Jim · CIK 0001813798 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 175,935 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on May 23, 2023. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 21:25 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 1,562 | $64.29 | $100,425.67 |
DisclosureSEC source: 0001209191-24-000780 · doc4.xml · nonDerivative · entry 4 Wassil Jim · CIK 0001813798 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 176,045 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on May 23, 2023. F4 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $64.13 to $64.99. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 21:25 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 1,039 | $63.55 | $66,025.33 |
DisclosureSEC source: 0001209191-24-000780 · doc4.xml · nonDerivative · entry 3 Wassil Jim · CIK 0001813798 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 177,607 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on May 23, 2023. F3 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $63.13 to $63.885. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 21:25 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 289 | $62.71 | $18,123.19 |
DisclosureSEC source: 0001209191-24-000780 · doc4.xml · nonDerivative · entry 2 Wassil Jim · CIK 0001813798 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 178,646 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on May 23, 2023. F2 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $62.01 to $62.94. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 21:25 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 3,000 | $2.42 | $7,260.00 |
DisclosureSEC source: 0001209191-24-000780 · doc4.xml · nonDerivative · entry 1 Wassil Jim · CIK 0001813798 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 178,935 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 01, 2023 Filed Dec 5, 2023 21:16 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 3,000 | $0.00 Strike: $2.42 | $0.00 |
DisclosureSEC source: 0001209191-23-057402 · doc4.xml · derivative · entry 4 Wassil Jim · CIK 0001813798 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 96,555 Underlying: Common Stock · 3,000 shares Expires 2029-12-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 1/4 of the shares subject to the option vested on December 1, 2020, and 1/48 of the shares vest monthly thereafter. Read SEC document |
| December 01, 2023 Filed Dec 5, 2023 21:16 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 1,933 | $52.51 | $101,499.90 |
DisclosureSEC source: 0001209191-23-057402 · doc4.xml · nonDerivative · entry 3 Wassil Jim · CIK 0001813798 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 175,935 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on May 23, 2023. F3 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $52.18 to $52.925. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.